Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

OBJECTIVES: To assess efficacy and safety of rituximab (RTX) as induction therapy, maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) patients. METHODS: Nationwide retrospective multicenter study of IgG4-RD patients treated with at least one course of RT...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Ebbo, Mikael, Grados, Aurélie, Samson, Maxime, Groh, Matthieu, Loundou, Anderson, Rigolet, Aude, Terrier, Benjamin, Guillaud, Constance, Carra-Dallière, Clarisse, Renou, Frédéric, Pozdzik, Agnieszka, Labauge, Pierre, Palat, Sylvain, Berthelot, Jean-Marie, Pennaforte, Jean-Loup, Wynckel, Alain, Lebas, Céline, Le Gouellec, Noémie, Quémeneur, Thomas, Dahan, Karine, Carbonnel, Franck, Leroux, Gaëlle, Perlat, Antoinette, Mathian, Alexis, Cacoub, Patrice, Hachulla, Eric, Costedoat-Chalumeau, Nathalie, Harlé, Jean-Robert, Schleinitz, Nicolas
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2017
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600376/
https://ncbi.nlm.nih.gov/pubmed/28915275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0183844
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items